Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2007

View Archived Issues

Dose-dependent occupancy of brain CB-1 receptors seen with taranabant

Positive results for XenoPort's phase I safety trials of XP-19986

Positive results for Vernalis' phase I V-24343 program for weight loss

Targeting Fyn protein kinase could lead to novel antipsychotic drugs

Targeting IL-23 shows benefit in models of multiple sclerosis in vivo

Allon provides clinical update

XOMA-052 enters clinic for type 2 diabetes

Genmab reveals HuMax-Inflam target

Patient dosing with OTS-102 begins at OncoTherapy Science

Adlea enters phase II clinical evaluation for TKA

FDA continues review of Entereg; clinical hold continues

Targanta to evaluate simplified oritavancin dosing regimens in phase II

AlphaRx to evaluate iNOS inhibitor for inflammation in preclinical studies

Patient enrollment begins in lubiprostone phase III clinical study for OBD

Spectrum's NDA for ISO-Vorin nears FDA decision

Isis and Ortho-McNeil establish antisense drug development collaboration

Positive phase I results encourage Pharmacopeia to expand dose of PS-433540

Ziopharm begins dosing patients in phase I trials of oral ZIO-101 and ZIO-301

Repros' IND for Proellex approved; phase II trial being planned

Research agreement for stem cell delivery to damaged organs signed

Targeting PPARalpha shows benefit in a model of circadian rhythm sleep disorder

Health Canada accepts new drug submission of ceftobiprole for cSSSI

Eli Lilly's Evista approved by FDA for new indication

Recent Taisho and Daiichi patents impart new therapeutic agents for autoimmune diseases

Recent patents disclose novel antiinfective agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...